DMCAF - DiaMedica Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4923
-0.0377 (-7.11%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close0.5300
Open0.5198
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4790 - 0.5340
52 Week Range0.1799 - 0.6887
Volume761,305
Avg. Volume247,196
Market Cap78.059M
Beta-0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research2 months ago

    DMA.V: What Does the Shanghai Pharma Acquisition Mean to DiaMedica?

    On May 21, 2018, Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH, 2607.HK) announced that the Company entered into a Share Purchase Agreement with Takeda  Pharma AG. Pursuant to the agreement, Shanghai Pharma, through its Hong Kong subsidiary Shanghai Pharmaceuticals (HK), will acquire 100% equity interest of a wholly-owned subsidiary of  Takeda  AG with a consideration of US$144 million, resulting in its indirect acquisition of 26.34% shares of  Techpool Bio-pharma Co., Ltd. (Techpool). Upon completion of the Proposed Acquisition, the shareholding in Techpool  by Shanghai Pharma will be increased from 40.80% to 67.14% and Shanghai Pharma would achieve absolute control of Techpool.

  • GlobeNewswire3 months ago

    DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (DMCAF), a clinical stage biopharmaceutical company focused on improving lives of patients with neurological and kidney diseases associated with low KLK1 levels, announced receipt of the final minutes from an in-person Type B meeting, with the Office of Drug Evaluation, Cardiovascular and Renal Division, of the U.S. Food and Drug Administration (FDA). The objective of the meeting was to gain feedback and recommendations from the FDA on DiaMedica’s planned clinical study of DM199 in patients with chronic kidney disease (CKD).

  • ACCESSWIRE4 months ago

    DiaMedica to Present at the MicroCap Conference on April 10th in New York City at the Essex House

    MINNEAPOLIS, MN / ACCESSWIRE / April 3, 2018 / DiaMedica Therapeutics Inc. (''DiaMedica'') (TSX-V: DMA) (OTCQB: DMCAF), today announced that Mr. Rick Pauls, President and CEO, will present at The MicroCap ...

  • Zacks Small Cap Research7 months ago

    V.DMA: New Financing Boosts Balance Sheet and Validates Clinical Programs

    On Dec. 13, 2017, DiaMedica (TSX:DMA.V) announced a non-brokered private placement. Per the news release, each unit included one common share and one-half of one common share purchase warrant. This share offering was offered on a non-brokered private placement basis to accredited investors.

  • DMA.V: Partnership will Accelerate the Development of DM199
    Zacks Small Cap Research8 months ago

    DMA.V: Partnership will Accelerate the Development of DM199

    Recently, DiaMedica entered into a non-binding term sheet with a large China-based pharmaceutical company for potential licensing rights in China. The Company is continuing ongoing discussions with potential partners in Asia.

  • Zacks Small Cap Research9 months ago

    DiaMedica (DMA.V): New Financing Will Accelerate Development of Clinical Programs

    On October 27, 2017, DiaMedica Therapeutics (DMA.V) announced that the company received approximately USD$605,263 in gross proceeds from the early exercise of 2,631,579 April 2017 warrants at USD$0.23 (CAD$0.31) per share. Also, in April, DiaMedica completed a non-brokered private placement with a prominent U.S. investor. In that placement, DiaMedica issued 10,526,315 units to the investor at an issue price of USD$0.19 (CAD$0.25) per unit.

  • Zacks Small Cap Research10 months ago

    DiaMedica (DMA.V) Initiates Phase II Trial of DM199 in Patients with Acute Ischemic Stroke

    On September 11, 2017, DiaMedica (DMA.V) announced the initiation of a Phase II REMEDY clinical trial assessing the safety, tolerability, and markers of therapeutic activity of DM199 (recombinant human KLK1) in patients suffering from acute ischemic stroke (AIS). REMEDY is a multi-center, double-blind, randomized, placebo-controlled Phase II clinical trial investigating DM199 treatment in patients who have suffered a moderate to moderately severe acute ischemic stroke.